Assessment of surveillance versus etiologic factors in the reciprocal association between papillary thyroid cancer and breast cancer |
| |
| Institution: | 1. Radiation Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD, USA;2. Division of Metabolism, Endocrinology, and Diabetes and Division of Hematology/Oncology, University of Michigan, Ann Arbor, MI, USA;1. Infectious Diseases Institute, Makerere University College of Health Sciences, Kampala, Uganda;2. Harvard Medical School, Boston, MA, United States;3. Moi University, Eldoret, Kenya;4. Academic Model Providing Access to Healthcare (AMPATH), Eldoret, Kenya;5. University of California, San Francisco, CA, United States;6. Masaka Regional Referral Hospital, Masaka, Uganda;7. Mbarara Regional Referral Hospital, Mbarara, Uganda;8. Indiana University, Indianapolis, IN, United States;1. Institute for Cancer Epidemiology, University of Lübeck, Ratzeburger Allee 160, 23562, Lübeck, Germany;2. Danish Cancer Society, Strandboulevarden 49, 2100, København, Denmark;1. Channing Division of Network Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA;2. Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA;3. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA;4. Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, USA;5. Department of Population Health Sciences, Weill Cornell Medicine, New York, NY, USA;1. Cancer Epidemiology Division, Cancer Council Victoria, Melbourne, Australia;2. School of Public Health, University of Queensland, Brisbane, Australia;3. Population Health Department, QIMR Berghofer Medical Research Institute, Brisbane, Australia;4. University Paris-Saclay, UVSQ, Inserm, Gustave Roussy, \"Exposome and Heredity\" team, CESP UMR1018, 94805, Villejuif, France;5. Department of Statistics, Computer Science and Applications (DISIA), University of Florence, Florence, Italy;6. University of Sydney, New South Wales, Australia;7. Faculty of Medicine, Nursing and Health Sciences, Monash University, Clayton, Victoria, Australia;8. Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Australia;9. University of Adelaide, Royal Adelaide Hospital, South Australia, Australia;10. Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia;11. Sir Peter MacCallum Department of Oncology, University of Melbourne, Australia;12. Eastern Health, Victoria, Australia;13. Hereditary Cancer Centre, Prince of Wales Hospital, Sydney, Australia / Prince of Wales Clinical School UNSW, Australia;14. University of Newcastle, Newcastle, Australia;15. Precision Medicine, School of Clinical Sciences, Monash Health, Monash University, Clayton, Victoria, Australia;p. Genomic Medicine, Royal Melbourne Hospital, Parkville, Australia;q. Department of Medicine, RMH, The University of Melbourne, Australia;1. Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Paediatric Oncology and Haematology, Germany;2. Charité-Universistätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Institute of Social Medicine, Epidemiology and Health Economics, Germany;3. Charité-Univesristätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Institute of Biometry and Clinical Epidemiology (iBiKE), Germany;4. St. Anna Kinderspital Vienna, Austria;5. University Hospital Hradec Králové, Czech Republic;6. University Hospital Ostrava, Czech Republic;7. University Hospital Brno, Czech Republic;8. Medical University Bialystok, Poland;9. University Hospital Motol, Prague, Czech Republic;10. Medical University Graz, Austria;11. University of Lucerne, Department of Health Sciences and Medicine, Switzerland;12. Medical University Wroclaw, Poland;13. Kepler Universitätsklinikum GmbH, Linz, Austria;14. Eastern Switzerland University of Applied Sciences, Department of Health Sciences, Institute of Applied Nursing Science, St. Gallen, Switzerland;15. Berlin Institute of Health (BIH), Berlin, Germany;1. University of Ioannina, Stavros Niarchou Avenue, Ioannina 45110, Greece;2. Gustave Roussy, Département de médecine oncologique, F-94805 Villejuif, France;3. Department of Hematology-Oncology, Faculty of Medicine, Saint Joseph University, Beirut 166830, Lebanon;4. Department of Medical Oncology, Antwerp University Hospital, Edegem, Belgium;5. Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium;6. King’s College London, Faculty of Life Sciences & Medicine, School of Cancer & Pharmaceutical Sciences, SE1 9RT London, UK;7. Medway NHS Foundation Trust, Windmill Road, Gillingham, Kent ME7 5NY, UK;8. AELIA Organization, 9th Km Thessaloniki-Thermi, Thessaloniki 57001, Greece;9. School of Community Health Sciences, University of Nevada, Reno, NV, USA |
| |
| Abstract: | BackgroundMutually increased risks for thyroid and breast cancer have been reported, but the contribution of etiologic factors versus increased medical surveillance to these associations is unknown.MethodsLeveraging large-scale US population-based cancer registry data, we used standardized incidence ratios (SIRs) to investigate the reciprocal risks of thyroid and breast cancers among adult females diagnosed with a first primary invasive, non-metastatic breast cancer (N = 652,627) or papillary thyroid cancer (PTC) (N = 92,318) during 2000–2017 who survived ≥1-year.ResultsPTC risk was increased 1.3-fold N = 1434; SIR = 1.32; 95 % confidence interval (CI) = 1.25–1.39] after breast cancer compared to the general population. PTC risk declined significantly with time since breast cancer (Poisson regression = Ptrend <0.001) and was evident only for tumors ≤2 cm in size. The SIRs for PTC were higher after hormone-receptor (HR)+ (versus HR-) and stage II or III (versus stage 0-I) breast tumors. Breast cancer risk was increased 1.2-fold (N = 2038; SIR = 1.21; CI = 1.16–1.26) after PTC and was constant over time since PTC but was only increased for stage 0-II and HR + breast cancers.ConclusionAlthough some of the patterns by latency, stage and size are consistent with heightened surveillance contributing to the breast-thyroid association, we cannot exclude a role of shared etiology or treatment effects. |
| |
| Keywords: | Breast cancer Papillary thyroid cancer Reciprocal association Surveillance Shared etiology Second cancer |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
